pSivida says U.K. NICE recommends Iluvien as treatment option pSivida (PSDV) announced that the United Kingdom’s National Institute for Health and Care Excellence issued final draft guidance recommending Iluvien as an option for the treatment of chronic diabetic macular edema that is insufficiently responsive to available therapies in pseudophakic eyes. This recommendation reverses the final draft guidance previously issued by NICE with respect to this subgroup of chronic DME patients. NICE’s final guidance recommending Iluvien to the National Health Service is expected to be published in November, which would result in NHS reimbursement in England and Wales under the patient access scheme submitted by Alimera Sciences (ALIM), pSivida’s licensee
News For PSDV;ALIM From The Last 14 Days
Check below for free stories on PSDV;ALIM the last two weeks.